Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) << sorafenib >>, sunitinib, and AG013736, which target multiple [[ VEGFRs ]] as well as PDGFR-beta.